Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411801 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)
A Phase 3 study, sponsored by Octapharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT00411801: Clinical Trial Phase 3 study, sponsored by Octapharma.
NCT00411801 is a Phase 3 study that was terminated before completion, run by Octapharma. The registered enrollment target is 8 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00411801, a Phase 3 study, was terminated before completion, sponsored by Octapharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
Prior to the use of plasma products, thrombotic thrombocytopenic purpura (TTP) was usually a fatal condition. During plasma exchange therapy, patients need transfusion plasma that is blood group specific. Transfusing a patient with an incorrect blood group may have fatal consequences. Uniplas is a universally applicable human plasma, which can be administered irrespective of the patient's blood group. This study will test the safety and efficacy of Uniplas in comparison to cryosupernatant plasma in treatment of patients with TTP.
Primary Outcome
Log platelet count was reported in units, where 1 unit = 10\^9/L platelets.
Interventions
- BIOLOGICAL Uniplas
- BIOLOGICAL Cryosupernatant plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Why NCT00411801 stopped before completion
NCT00411801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Uniplas is the first listed.
NCT00411801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00411801 about?
NCT00411801 is a clinical study titled "Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)". Prior to the use of plasma products, thrombotic thrombocytopenic purpura (TTP) was usually a fatal condition. During plasma exchange therapy, patients need transfusion plasma that is blood group specific. Transfusing a patient with an incorrect blood group may have fatal consequences. Uniplas is a u...
What is the current status of trial NCT00411801?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2007-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00411801?
The interventions under investigation include: Uniplas (BIOLOGICAL), Cryosupernatant plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00411801?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00411801's enrollment target sits among peer trials
8 1993rd of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia